480
Participants
Start Date
September 21, 2020
Primary Completion Date
February 5, 2025
Study Completion Date
February 5, 2025
dolutegravir
One daily tablet (50mg) during 96 weeks
atazanavir boosted with ritonavir
One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks
tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir
One daily tablet with tenofovir 245 mg + lamivudine (300 mg) + efavirenz (400 mg) during 96 weeks OR One daily tablet with dolutegravir 50 mg + lamivudine (300 mg) + tenofovir (300 mg) during 96 weeks
Lamivudine
One daily tablet (300mg) during 96 weeks
Hôpital de jour, Service des maladies infectieuses, CHU Sourô Sanou, Bobo-Dioulasso
Service de médecine interne, CHU Yalgado Ouédraogo, Ouagadougou
Service des Maladies Infectieuses, Hôpital du jour, Hôpital Central, Yaoundé
Centre de Prise en Charge et de Formation (CePReF), Association ACONDA, Abidjan
Service des Maladies Infectieuses et Tropicales (SMIT), CHU de Treichville, Abidjan
Collaborators (1)
Mylan Laboratories
INDUSTRY
ANRS, Emerging Infectious Diseases
OTHER_GOV